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Abstract
Inflammatory β-cell failure contributes to type 1 and type 2 diabetes pathogenesis. Pro-
inflammatory cytokines cause β-cell dysfunction and apoptosis, and lysine deacetylase
inhibitors (KDACi) prevent β-cell failure in vitro and in vivo, in part by reducing NF-κB tran-
scriptional activity. We investigated the hypothesis that the protective effect of KDACi
involves transcriptional regulation of microRNAs (miRs), potential new targets in diabetes
treatment. Insulin-producing INS1 cells were cultured with or without the broad-spectrum
KDACi Givinostat, prior to exposure to the pro-inflammatory cytokines IL-1β and IFN-γ for 6
h or 24 h, and miR expression was profiled with miR array. Thirteen miRs (miR-7a-2-3p,
miR-29c-3p, miR-96-5p, miR-101a-3p, miR-140-5p, miR-146a-5p, miR-146b-5p, miR-340-
5p, miR-384-5p, miR-455-5p, miR-466b-2-3p, miR-652-5p, and miR-3584-5p) were regu-
lated by both cytokines and Givinostat, and nine were examined by qRT-PCR. miR-146a-5p
was strongly regulated by cytokines and KDACi and was analyzed further. miR-146a-5p
expression was induced by cytokines in rat and human islets. Cytokine-induced miR-146a-
5p expression was specific for INS1 and β-TC3 cells, whereas α-TC1 cells exhibited a
higher basal expression. Transfection of INS1 cells with miR-146a-5p reduced cytokine sig-
naling, including the activity of NF-κB and iNOS promoters, as well as NO production and
protein levels of iNOS and its own direct targets TNF receptor associated factor 6 (TRAF6)
and interleukin-1 receptor-associated kinase 1 (IRAK1). miR-146a-5p was elevated in the
pancreas of diabetes-prone BB-DP rats at diabetes onset, suggesting that miR-146a-5p
could play a role in type 1 diabetes development. The miR array of cytokine-exposed INS1
cells rescued by KDACi revealed several other miRs potentially involved in cytokine-induced
β-cell apoptosis, demonstrating the strength of this approach.
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Introduction
Reduction of functional β-cell mass is a feature of both type 1 and type 2 diabetes (T1D and
T2D, respectively), and inflammatory mechanisms including pro-inflammatory cytokines
have been implicated as mediators of β-cell apoptosis in both disorders [1–3]. The pro-inflam-
matory cytokines interleukin-1β (IL-1β), interferon-γ (IFN-γ) and tumor necrosis factor-α
(TNF-α) in synergy cause selective β-cell destruction in vitro [4–6]. The process involves endo-
plasmic reticulum, and mitochondrial and oxidative stress-induced apoptosis [7, 8] dependent
on activation of mitogen activated protein kinases (MAPK) and the nuclear factor kappa B
(NF-κB) transcription factor [9–11]. However, the exact mechanisms behind cytokine-
induced β-cell death are not fully understood.
Cytokine-induced β-cell apoptosis requires active gene expression and protein translation
[11]. We recently discovered that oral inhibitors of lysine deacetylases (KDACs), proven to be
effective and safe in other inflammatory disorders such as systemic onset juvenile idiopathic
arthritis [12] and graft-versus-host disease [13], prevent cytokine-induced β-cell apoptosis
[14–19]. KDACs are enzymes that regulate gene expression and protein activity by deacetylat-
ing histone proteins, transcription factors, kinases, and other proteins [20, 21]. We found that
all 11 classical KDACs are expressed and differentially regulated in β-cells, and that the β-cell
protective effect of broad KDACi in vitro and in vivo was mainly conferred by inhibition of his-
tone deacetylases 1 and 3 (HDAC1 and HDAC3) [15, 18, 19]. The protection was not associ-
ated with upregulation of gene expression as expected from the conventional concept that
histone hyperacetylation leads to a more open chromatin structure accessible to the transcrip-
tional machinery, but with downregulation of inflammatory gene expression [18]. KDACi
caused hyperacetylation and thereby reduced NF-κB binding to inflammatory promoters, in
part providing a molecular mechanism of action [14]. However, an additional mechanism
could be hyperacetylation of histones upregulating expression of anti-apoptotic microRNAs
(miRs). These in turn could act by e.g. repressing the translation of proteins that promote β-
cell death via activation of the intrinsic (mitochondrial) death pathway.
miRs are small conserved non-coding RNAs that regulate translation and stability of spe-
cific target mRNAs [22]. miRs have been associated with a number of biological processes
such as organ development, maturation and apoptosis in the immune system [23]. Impor-
tantly, several studies have implicated miRs in β-cell biology, diabetes, insulin resistance, and
inflammation [24, 25]. We therefore aimed to identify miRs involved in cytokine-induced β-
cell apoptosis by profiling miR regulation in insulin-producing cells exposed to inflammatory
stress in the absence and presence of KDACi and validating the functional importance of can-
didate miRs in insulin-secreting cells and rodent and human islets, as moderating such miRs
could be new promising approaches to future diabetes treatments.
Materials and methods
Cell culture
The rat insulinoma-derived β-cell line INS1 and the INSrαβ cell line, a maturation model with
inducible pancreatic duodenal homeobox-1 (Pdx-1) expression, were generous gifts from
Claes Wollheim and Pierre Maechler (University of Geneva, Switzerland). α-TC1, β-TC3 and
INS1 cells were maintained in RPMI-1640 medium with GlutaMAX (Life Technologies), sup-
plemented with 10% fetal bovine serum (FBS, Life technologies), 100 U/ml penicillin and
100 μg/ml streptomycin (1% P/S, Life Technologies), and 50 μM β-mercaptoethanol (Life
Technologies). The cells were cultured at 37˚C in a humidified atmosphere containing 5%
CO2. Changing medium and passaging of cells were performed weekly. Studies with the
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INSrαβ cell line were performed as described previously [26]. All cells were Mycoplasma
negative.
Rat islets and pancreas
Islets were isolated from 3 to 6 day-old neonatal Wistar rat pups (Taconic, Ry, Denmark). The
islets were cultured in RPMI-1640 medium with GlutaMAX (Invitrogen) supplemented with
1% P/S and 10% newborn calf serum (Invitrogen). Islets were transferred to new medium and
100 randomly picked islets per well were placed in 12-well plates and exposed for 2, 6 or 24 h
to IL-1β (160 pg/ml, Sigma) alone or a mixture of IFN-γ (5 ng/ml, BD-Pharm) and IL-1β (160
pg/ml, Sigma).
BB-DP rats (M&B, Ll. Skensved, Denmark) were housed in a specific pathogen-free envi-
ronment under controlled conditions of light and temperature with unlimited access to food
and water [27]. The rats were weighed and blood glucose (BG) was measured thrice weekly.
When BG was higher than 14 mmol/l it was checked the next day, and diabetes defined as
BG> 14 mmol/l on two consecutive days. The rats were sacrificed at 37, 53, 80 or 120 days of
age or at onset of diabetes. The mean age of diabetes onset was 81 days of age. Immediately
after sacrifice, the pancreas was removed, snap-frozen and stored at -80˚C until RNA extrac-
tion (n = 3–6 in each group).
Animal experiments, including anesthesia, were performed according with Danish veteri-
narian guidelines for animal care and welfare and were approved by the Danish Animal Exper-
iment Inspectorate. No survival surgeries were performed. An IACUC (Institutional Animal
Care and Use Committee) supervised all animal procedures. All principal decisions concern-
ing the Animal Care and Use Programme in the mentioned fora are worked into Standard
Operating Procedures. The Department’s animal care and use programme is accredited by
AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) Interna-
tional. Refinement principles for animal models and experimental procedures were employed
to maximize animal welfare and to optimize the experimental outcome of animal experiments.
The research is aligned with the principles of the 3R’s: Replacement, Reduction, and Refine-
ment. The University of Copenhagen is registered with the National Institutes of Health, the
Animal Welfare Assurance Number is F16-00203 (A5846-01).
Human islets
Human pancreatic islets of Langerhans isolated by collagenase digestion were received from
the European Consortium for Islet Transplantation (ECIT), hand-picked, and maintained in
RPMI-1640 medium w/o glucose supplemented with 10% FBS, 1% P/S and 5.6 mM D-glucose
(Life Technologies). For experiments, a mixture of TNF-α, IL-1β and IFN-γ was generally
used to exploit the synergy between these three cytokines for induction of more robust
responses, since human islets are more resistant to cytokines than mouse and rat islets [1].
Human pancreatic islets were used for quantitative real time PCR (qRT-PCR) of miR-146a-5p.
Islets from nine non-diabetic necrodonors, five from male donors and three from female
donors (age 8–57 years), were exposed for 48 h to a mixture of TNF-α (5000 U/ml, Peprotech),
IFN-γ (750 U/ml, BD Pharmingen) and IL-1β (75 U/ml, Sigma).
In addition, islets were obtained from three different non-diabetic necrodonors, one 64
year-old male and two 22 and 52 year-old females, respectively. Threehundred and fifty islets
per condition were transferred to medium at receipt as described above but with 2% human
serum instead of FBS. After a 24 h pre-incubation, the islets were treated with or without 500
nM Givinostat (SelleckChem) 1 h prior to cytokine exposure to a mixture of 300 pg/ml
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recombinant mIL-1β (R&D systems), 10 ng/ml recombinant hIFN-γ (BD Biosciences) and 10
ng/ml recombinant hTNF-α (Peprotech) for 24 h.
Microarray analysis
INS1 cells were seeded in 6-well plates, incubated for 48 h, and left untreated, treated with 125
nM Givinostat (Giv) 1 h prior to the addition of 150 pg/ml IL-1β and 0.1 ng/ml IFN-γ (Cyt) or
no cytokines (ctrl) for 6 h or 24 h. miR-enriched total RNA was purified with the miRCURY™
RNA Isolation Cell and Plant Kit (Exiqon). The samples for microarray screening were divided
into 8 groups (6h_Ctrl, 6h_Cyt, 6h_Giv_Ctrl, 6h_Giv_Cyt, 24h_Ctrl, 24h_Cyt, 24h_Giv_Ctrl,
and 24h_Giv_Cyt) with each group containing three replicates. A total of 24 samples where
hybridized to SurePrint G3 8x15k Rat miRNA Agilent microarray (G4473C). The microarray
platform contained 12843 probes including 434 negative controls, 281 positive controls, and
12128 miRs. A total of 758 unique miRs were present on the array and each miR represented
by 16 probes.
The microarray data analyses were performed using Bioconductor packages in R program-
ming language [28]. The microarray quality control was assessed using the R Bioconductor
package arrayQualityMetrics [29]. Raw data import and normalization together with differen-
tial expression analysis was performed using the R Bioconductor package limma [30]. The sig-
nal intensity of each probe on each array was quantified by taking the median foreground
signal with no background correction. Subsequently all arrays were filtered to remove control
probes and were normalized using the quantile normalization method which sets intensities to
have the same empirical distribution across arrays. The differential expression analysis was
performed in limma where a moderated t-statistic is computed for each contrast for each
probe. Limma performs the multiple probe-to-miR mapping using a pooled correlation
method, where correlation among replicated miR probes is taken into account in the model.
Differentially expressed miRs were identified in the following 12 contrasts: 6h_Cyt vs 6h_Ctrl,
6h_Giv_Cyt vs 6h_Cyt, 6h_Giv_Cyt vs 6h_Giv_Ctrl, 6h_Giv_Ctrl vs 6h_Ctrl, 24h_Cyt vs
24h_Ctrl, 24h_Giv_Cyt vs 24h_Cyt, 24h_Giv_Cyt vs 24h_Giv_Ctrl, 24h_Giv_Ctrl vs 24h_Ctrl,
24h_Cyt vs 6h_Cyt, 24h_Giv_Cyt vs 6h_Giv_Cyt, 24h_Ctrl vs 6h_Ctrl and 24h_Giv_Ctrl vs
6h_Giv_Ctrl. p-values were adjusted for multiple correction using Benjamini and Hochberg’s
method. A cutoff of abs-log2(FC) >0.1375 and adjusted p-value <0.05 were used to identify
differentially expressed miRs in each contrast. The cutoff for log2(FC) corresponds to a fold
change of 1.15, and since the dynamic range of microarray is not as high as for qRT-PCR, a
fold change of 1.15 on microarray normally corresponds to a much higher change in qRT-PCR
validated miR levels. Further, for miR qRT-PCR data, a fold change of 1.2 is generally used as
cutoff instead of the 2-fold cutoff for mRNAs, since it is believed that small differences in miR
levels are sufficient for the fine-tuning of the transcriptional system executed by miRs. Various
studies have shown miRs with a fold change ~1.2 to be biologically relevant [31, 32].
RNA purification and qRT-PCR evaluation of miRs
INS1 cells were seeded in 6-well plates, incubated for 48 h, and left untreated, treated with
1 μM of the KDACi CI994 or 125 nM Givinostat (Giv) 1 h prior to the addition of 150 pg/ml
IL-1β and 0.1 ng/ml IFN-γ (Cyt) or no cytokines for 6 h, 18 h or 24 h. miR-enriched total RNA
was purified with the miRCURY™ RNA Isolation Cell and Plant Kit (Exiqon). SYBR Green-
based qRT-PCR quantification of specific miRs was performed using the Universal cDNA Syn-
thesis Kit II and ExiLENT SYBR1 Green master mix (Exiqon) according to the manufacturer’s
protocols with the following modifications: 20 ng/μl total RNA in 10 μl cDNA reactions, and
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40X cDNA dilutions in 10 μl qPCR reactions were used. Primer efficiencies were all in the
range of 90–108%.
RNA purification and qRT-PCR for miR-146a-5p, TRAF6 and IRAK1
RNA was extracted using TRIZOL reagent (Invitrogen), as described by the manufacturer.
RNA quality and concentration was measured on a NanoDrop 1000 (Thermo Scientific).
cDNA for qRT-PCR was prepared using the TaqMan1 Reverse Transcription kit (Applied
Biosystems), according to the manufacturer’s protocol. cDNA for mature miR expression was
prepared using TaqMan1 microRNA Reverse Transcription kit (Applied Biosystems) accord-
ing to a protocol optimized for multiplex reactions with up to four miR primer sets. CT level
did not differ when comparing singleplex and multiplex reactions. The cDNA synthesis was
performed on an ABI thermal cycler 3100 (Applied Biosystems).
Gene and miR expressions were analyzed by qRT-PCR using SYBR green and TaqMan
assays (Applied Biosystems), as described by the manufacturer. Samples were analyzed in
duplicates on an ABI 7900 HT platform (Applied Biosystems). Data was examined using the
SDS 2.1 software (Applied Biosystems) and evaluated by the 2-ΔΔCt method described in [33].
The internal control gene PPIA was used for normalizing TRAF6 and IRAK1 expression. Let-
7c was tested thoroughly for stable expression during cytokine treatment and used as internal
control for normalizing miR-146a-5p expression in samples from human, rat and mouse.
Alternatively, the geometric mean of miR-103a and miR-423 was used, as indicated in the fig-
ure legends.
Western blotting
Protein concentrations were measured by the Bradford method, according to the manufactur-
er’s instructions (BioRad). Samples containing equal amounts of protein were prepared with
loading buffer and boiled before loading on a Nupage Novex gel (Invitrogen). The gel was
placed in an X-cell Surelock system (Invitrogen), and proteins were separated. The proteins
were then transferred to a nitrocellulose membrane (Invitrogen), which was blocked in skim
milk or BSA. Primary antibodies were preabsorbed with milk or BSA. Visualization involved
HRP-linked secondary antibodies. Proteins of interest were detected with Lumi-GLO (Cell
Signaling) and visualized using a LAS3000 imaging system (Fuji Film). Antibodies were rabbit
anti-TRAF6 (Santa Cruz, #sc-7221), rabbit anti-inducible nitric oxide synthase (iNOS) (BD
Biosciences, #610332), rabbit anti-IRAK1 (Abcam, #AB238), rabbit anti-phospho-c-Jun N-ter-
minal kinase 1/2 (JNK1/2) (Cell Signaling, #9251), rabbit anti-phospho-p38 (Cell Signaling,
#9211), rabbit anti-phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) (Cell Signaling,
#9101), and mouse anti-β-actin (Abcam, #AB6276-100). Anti-rabbit IgG (Cell Signaling,
#7074) and anti-mouse IgG (Abcam, #Ab6789) were used as secondary antibodies.
Luciferase promoter and 3’UTR constructs
Vectors with the luciferase gene and the native 3’untranslated region (3’UTR) construct of
TRAF6 or IRAK1, described in [34], were purchased from AddGene (www.Addgene.org). The
native iNOS promoter construct was described in [35], and the NF-κB promoter construct
(pNF-κB) containing a repetitive κB motive was purchased from Stratagene. The miR-146a-5p
promoter construct, described in [34], was also ordered from AddGene. The luciferase activity
was measured by a dual luciferase reporter assay system (Promega), according to the manufac-
turer’s protocol. The luciferase activity was normalized to a co-transfected vector (pRL-TK)
containing a HSV-TK promoter driven Renilla construct (Promega). Readings were con-
ducted on a luminometer from Berthold Technologies.
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Transfection with miR
INS1 cells were transfected with miR-146a-5p miRIDIAN mimics (#C-300630-03, Thermo
Scientific) or a negative control miR mimic (#CN-001000-01, Thermo Scientific) using Dhar-
maFECT 1 (Thermo Scientific) as transfection reagent. All transfections had a final oligo con-
centration of 30 nmol/l. Cell medium was changed at the day of transfection to medium
without antibiotics. In two separate tubes, OptiMEM (Invitrogen) was mixed with Dharma-
FECT-1 reagent and with synthetic oligos, and the two tubes were incubated for 5 min at room
temperature. The contents of the two tubes were mixed 1:1 and incubated at room temperature
for 20 min. The transfection solution was then diluted 1:5 with RPMI-1640 (Invitrogen) and
added to the cells. The transfection medium was removed after overnight incubation at 37˚C
in a humidified atmosphere of 5% CO2. The cells were then incubated for at least another 24 h.
Transfection efficiency was estimated to ~50% by co-transfection with a GFP expressing plas-
mid pMAX (Lonza). Furthermore, the expression level of the transfected miR mimic was
examined as a transfection control. For evaluation of miR overexpression in combination with
cytokine stimulation, cells were pre-treated with miR mimics for 48 h and then exposed to IL-
1β (160 pg/ml) for 30 min or 6 h.
Apoptosis
INS1 cells were left untreated, treated with 1 μM CI994 or 125 nM Givinostat 1 h prior to addi-
tion of 0.1 ng/mL IFN-γ plus 37–150 pg/mL IL-1β or no cytokines for 24 h. Apoptosis was
measured using the Cell Death Detection ELISA (Roche) according to the manufacturer’s
protocol.
Nitric oxide (NO) measurements
The INS1 cell production of NO was measured as accumulated nitrite in the culture medium
using the Griess reagent, since NO is rapidly converted to nitrite. Supernatants from stimu-
lated cells were mixed with equal volumes of cell culture medium and Griess reagent (0.1%
[wt/vol.] naphthylethene diamine hydrochloride; Sigma) in H2O, and 1% (wt/vol.) sulphanila-
mide (Bie & Berntsen) in 5% (vol./vol.) H3PO4 (Merck). Absorbance was measured at 550 nm,
and accumulated nitrite was calculated from a NaNO2 standard curve [19].
miR target prediction and bioinformatics analysis
The CyTargetLinker plugin v 3.01 [36] within Cytoscape [37] was used for identifying molecu-
lar targets for each miR and to create miR-target interaction (MTI) networks. Regulatory inter-
action networks (RegIN) were created within CyTargetLinker in Cytoscape using Homo
sapiens MTIs from one experimentally validated miR-target resource miRTarBase v6.1 [38]
which includes 410,602 MTIs, and one predicted miR-target resource TargetScan v6.2 [39],
which includes 511,040 MTIs. Only those targets were kept that were supported by both of
these resources and visualized in networks.
Functional annotation clustering module in DAVID (the Database for Annotation, Visuali-
zation, and Integrated Discovery) [40] was used to cluster similar gene ontology (GO) annota-
tion terms associated with the identified miR-targets into functionally annotated clusters.
GO-Fat biological process (BP) categories were used for the analysis. An EASE score (modified
Fisher’s exact t-test) cutoff of<0.01 and highest stringency classification was applied. A group
enrichment score in DAVID is calculated by taking the geometric mean (in -log scale) of each
member annotation term’s p-values in a corresponding annotation cluster. The enriched clus-
ters with group enrichment scores> 1.3 were selected.
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Statistical analysis
The microarray analyses were done in R programming language using the Bioconductor pack-
ages arrayQualityMetrics and limma, as described above. All other statistical analyses were car-
ried out in GraphPad Prism software v7.0 or Microsoft Excel. Two-tailed Student’s t-test was
used to analyze significant differences between two groups, unless otherwise stated. All one-
way or two-way ANOVA analyses were corrected for multiple testing using Bonferroni test. p-
values below 0.05 were considered statistically significant.
Results
KDAC inhibition regulates cytokine-induced miR expression
To investigate whether the mechanisms behind KDACi-mediated protection against cytokine-
induced apoptosis involve transcriptional regulation of miRs, we performed a miR array pro-
filing of 758 rat miRs (miRbase version 21.0). With the purpose of selecting the experimental
setup for the miR array, insulin-producing INS1 cells were cultured with or without the
KDACi CI994, an inhibitor selective for HDAC1, 2, and 3, or the broad-spectrum KDACi
Givinostat, prior to exposure to different concentrations of the pro-inflammatory cytokine IL-
1β (37–150 pg/ml) together with IFN-γ (0.1 ng/ml) for 6 h or 24 h. As seen in S1 Fig, both
CI994 and Givinostat reduced cytokine-induced cell death and NO production, confirming
previous results from our group and others [16, 19]. Given the higher efficacy of Givinostat in
lowering NO production, this KDACi was chosen for the miR array study. INS1 cells were
exposed to Givinostat or no treatment for 1 h and then to media with or without 150 pg/ml IL-
1β and 0.1 ng/ml IFN-γ for 6 h or 24 h. RNA extracted from control (Ctrl), cytokine (Cyt),
Givinostat+cytokines (Giv_Cyt), and Givinostat-cytokines (Giv_Ctrl) samples at 6 h and 24 h
were used in triplicates for miR array (Table 1). Table 1 shows the numbers of significantly reg-
ulated miRs following a cut-off of adjusted p<0.05 and log2(FC) > 0.1375, corresponding to a
fold change of 1.15, when analyzed for all 12 pairwise comparisons. The raw data from the
miR array are deposited at GEO database (GSE117451). As expected, the addition of cytokines
led to the largest change in miR expression profile, but only after 24 h. Remarkably, the addi-
tion of Givinostat also changed the expression of a substantial numbers of miRs.
We next analyzed which miRs were significantly regulated both by cytokines and by Givi-
nostat in the presence of cytokines. These were divided into four groups based on their regula-
tion patterns, as shown in Table 2.
To identify the potential targets of these groups of miRs we used CyTargetLinker plugin
within Cytoscape. miR-target interaction networks were created for the four selected groups of
miRs as listed in Table 2 (S2 Fig). From group A with three miRs, miR-7a-2-3p and miR-652-
5p did not have targets from the two target prediction resources used for this analysis (Fig A in
S2 Fig). In group B with 8 miRs, miR-340-5p did not have any targets (Fig B in S2 Fig). Inter-
estingly, the shared targets of miR-29c-3p, miR-96-5p, and miR-101-3p of group B were found
to be related to multiple cellular functions and interconnected in a larger network (Fig B in S2
Fig). miR-466 and miR-455-5p from Group A and B, respectively, formed discrete non-inter-
connected target networks (Figs A and B in S2 Fig). Of note, miR-146a-5p and miR-146b-5p
from group C and D formed discrete overlapping but not identical target networks (Fig C in
S2 Fig).
We next performed functional annotation clustering analysis based on biological process
(BP) gene ontology (GO) terms in DAVID. We searched for functional clusters of genes within
the target genes of the above mentioned four groups based on enriched BP terms. For group A
miR-targets, no enriched clusters were found. For group B miR-targets, seven significantly
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enriched clusters were found. The top enriched clusters for group B miR-targets were associ-
ated with negative regulation of transcription, regulation of apoptosis and cell-death processes
(S1 Table). In case of group C and D, three enriched clusters were found which represented
NF-κB-inducing kinase activity, regulation of phosphorylation and regulation of cell develop-
ment processes (S1 Table). These results highlight the involvement of miR-targets from group
B, C and D in various important cellular processes.
qRT-PCR validation of specific miRs
Out of the thirteen miRs regulated by both cytokines and Givinostat, nine representative miRs
were evaluated by qRT-PCR on INS1 cells treated similarly to the array samples but using both
CI994 and Givinostat and 6 h, 18 h, and 24 h exposure to cytokines (Fig 1). For group A
(Table 2), miR-7a-2-3p was confirmed to be downregulated after 24 h of cytokine exposure,
which was prevented by Givinostat (Fig 1). For group B, upregulation after 24 h and also 18 h
of cytokine exposure was confirmed for miR-29c-3p, miR-96-5p, miR-101a-3p, and miR-340-
5p. Givinostat did not significantly change their expression after 24 h of cytokine exposure.
However, Givinostat did significantly reduce the 18 h cytokine-induced expression of miR-
96-5p, miR-101a-3p, and also miR-455-5p, the latter also after 6 h of exposure (Fig 1). For
group D, cytokines persistently upregulated the expression of miR-146b-5p and the cytokine-
induced upregulation was prevented by Givinostat after 6 h of exposure, confirming the array
data (Fig 1).
Table 1. Summary of miR microarray results.
Comparison Biological significance of comparison # of miRs significantly regulated in
given comparisons
6 h_Cyt vs 6 h_Ctrl Regulated by cytokines at 6 h 2
6 h_Giv_Cyt vs 6
h_Cyt
Regulated by Giv.in presence of cytokines at 6 h 21
6 h_Giv_Cyt vs 6
h_Giv_Ctrl
Regulated by cytokines in presence of Giv. at 6 h -
6 h.Giv.Ctl vs 6 h_Ctrl Regulated by Giv.in absence of cytokines at 6 h 5
24 h_Cyt vs 24 h_Ctrl Regulated by cytokines at 24 h 48
24 h_Giv_Cyt vs 24
h_Cyt
Regulated by Giv. in presence of cytokines at 24 h 24
24 h_Giv_Cyt vs 24
h_Giv_Ctrl
Regulated by cytokines in presence of Giv. at 24 h 43
24 h_Giv_Ctrl vs 24
h_Ctrl
Regulated by Giv.in absence of cytokines at 24 h 3
24 h_Cyt vs 6 h_Cyt Difference in effects of cytokine exposure for 24 h
vs. 6 h
18
24 h_Giv_Cyt vs 6
h_Giv_Cyt
Difference in effects of Giv. exposure for 24 h vs. 6
h in the presence of cytokines
14
24 h_Ctrl vs 6 h_Ctrl Difference between 24 h vs. 6 h in absence of
cytokines and Giv.
5
24 h_Giv_Ctrl vs 6
h_Giv_Ctrl
Difference in effects of Giv. exposure for 24 h vs. 6
h in the absence of cytokines
2
The numbers denote significantly regulated miRs following a cut-off of adjusted p<0.05 and log2(FC) >0.1375,
corresponding to a fold change of 1.15. Shadings denote pairwise comparisons of interest regarding the scientific
hypothesis.
https://doi.org/10.1371/journal.pone.0203713.t001
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The most remarkable miR expression pattern was that of the related miR-146a-5p in group
C, which was highly upregulated at 6 h, 18 h and 24 h of exposure to cytokines (Fig 1). More-
over, ANOVA testing demonstrated significance between KDACi treatments and time of
exposure, with interactions between treatments and time of exposure (S2 Table). Confirming
the array data, Givinostat enhanced the cytokine-induced expression of miR-146a-5p at both
18 h and 24 h with 48% and 100%, respectively (Fig 1). In contrast, at 6 h, Givinostat reduced
the cytokine-induced expression of miR-146a-5p. CI994 had a similar but smaller effect at 6 h
and 24 h (Fig 1), reflecting the fact that this inhibitor targets only three KDAC enzymes,
whereas Givinostat targets all non-sirtuin KDACs.
Our results demonstrate that a number of miRs are subject to KDAC-dependent expres-
sional changes following cytokine treatment in INS1 cells. As miR-146a-5p was the most sig-
nificantly regulated miR by both cytokines and Givinostat we focused on this miR in the
following experiments.
KDACi reduces cytokine-mediated miR-146a-5p induction in human islets
We next wanted to confirm cytokine-mediated upregulation of miR-146a-5p in human pan-
creatic islets of Langerhans. qRT-PCR analysis showed that a mixture of cytokines significantly
upregulated miR-146a-5p expression in isolated human islets after 24 h of treatment (Fig 2A)
as well as after 48 h of treatment (Fig 2B). In contrast to the potentiating effect of Givinostat in
INS1 cells after 24 h of cytokine exposure, Givinostat reduced cytokine-induced miR-146a-5p
expression in human islets (Fig 2A). However, the results confirm that cytokine-induced miR-
146a-5p expression is subject to KDAC-dependent regulation in both rat insulin-secreting
INS1 cells and in human islets. Based on this, we chose to further investigate the underlying
mechanisms and functions of the cytokine-induced expression of miR-146a-5p.
miR-146a-5p expression is mainly induced by IL-1β
Next, we wished to detail further the induction of miR-146a-5p by IL-1β alone versus a mix-
ture of cytokines. The expression of miR-146a-5p in INS1 cells was markedly and significantly
Table 2. miRs regulated by cytokines and Givinostat.
Log2FC Adjusted p-value
Group MicroRNA Human ortholog 24 h_Cyt vs Ctrl 24 h_Giv_Cyt vs Cyt 24 h_Cyt vs Ctrl 24 h_Giv_Cyt vs Cyt
A: Cyt#, Giv", 24 h rno-miR-7a-2-3p hsa-miR-7-2-3p -0.22 0.36 8.90E-03 6.71E-06
rno-miR-466b-2-3p hsa-miR-466 -0.26 0.30 4.96E-02 3.29E-02
rno-miR-652-5p hsa-miR-652-5p -0.56 0.32 1.20E-27 2.66E-09
B: Cyt", Giv#, 24 h rno-miR-29c-3p hsa-miR-29c-3p 0.71 -0.20 5.75E-35 2.61E-03
rno-miR-96-5p hsa-miR-96-5p 0.70 -0.24 3.19E-36 6.24E-05
rno-miR-101a-3p hsa-miR-101-3p 0.60 -0.30 2.90E-33 7.85E-09
rno-miR-140-5p hsa-miR-140-5p 0.17 -0.13 5.05E-05 8.10E-03
rno-miR-340-5p hsa-miR-340-5p 0.39 -0.22 1.91E-24 5.44E-08
rno-miR-384-5p hsa-miR-384 0.38 -0.30 1.44E-09 2.48E-05
rno-miR-455-5p hsa-miR-455-5p 0.19 -0.15 6.91E-08 6.24E-05
rno-miR-3584-5p No human ortholog 0.38 -0.14 1.46E-32 2.68E-05
C: Cyt", Giv", 24 h rno-miR-146a-5p hsa-miR-146a-5p 0.59 0.16 5.17E-32 5.17E-32
Group MicroRNA Human ortholog 6 h_Cyt vs Ctrl 6 h_Giv_Cyt vs Cyt 6 h_Cyt vs Ctrl 6 h_Giv_Cyt vs Cyt
D: Cyt", Giv#, 6 h rno-miR-146b-5p hsa-miR-146b-5p 0.44 -0.42 5.70E-07 3.02E-06
miRs fulfilling the requirements to be regulated both by cytokines and by Givinostat in the presence of cytokines, sorted into groups.
https://doi.org/10.1371/journal.pone.0203713.t002
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Fig 1. Expression of selected miRs in INS1 cells. INS1 cells were left untreated, treated with 1 μM of the KDACi
CI994 or 125 nM Givinostat (Giv) 1 h prior to the addition of 150 pg/ml IL-1β and 0.1 ng/ml IFN-γ (Cyt) or no
cytokines for 6 h, 18 h or 24 h. MiR-enriched total RNA was purified, and the expression of specific miRs was
measured with qRT-PCR and normalized to the geometric mean of the housekeeping miRs miR-103a and miR-423.
Data are presented as mean ± SEM (n = 9–10) of 2-ΔCT. Statistical significance of a paired t-test is shown in the graphs
(p<0.05, p<0.01, p<0.001 and p<0.0001). Group A: miRs were Cyt#, Giv" at 24 h. Group 2: miRs were
Cyt", Giv# at 24 h. Group C: miR was Cyt", Giv" at 24 h. Group D: miR was Cyt", Giv# at 6 h.
https://doi.org/10.1371/journal.pone.0203713.g001
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upregulated upon stimulation with IL-1β alone for 6 h, 12 h or 24 h, respectively (Fig 3A). Nei-
ther TNF-α nor IFN-γ alone had a significant effect on miR-146a-5p expression at 8 h expo-
sure, whereas a mixture of IL-1β, IFN-γ and TNF-α for 8 h resulted in induction of miR-146a-
5p at levels only slightly higher than IL-1β alone (Fig 3B). We also examined the expression of
miR-146a-5p in rat islets exposed to cytokines. miR-146a-5p was induced by IL-1β alone and
more profoundly so by a combination of IL-1β, IFN-γ and TNF-α in a time-dependent man-
ner with peak induction at the latest time point of 24 h (S3 Fig).
Using constructs containing the native human miR-146a-5p promoter driving Firefly lucif-
erase expression as previously described [34], we investigated whether IL-1β alone or in com-
bination with IFN-γ was able to induce expression of the luciferase gene. We found that 6 h of
cytokine stimulation significantly induced the Firefly luciferase expression through the miR-
146a-5p promoter, both by IL-1β alone and slightly more by a mixture of IL-1β, IFN-γ and
TNF-α (Fig 3C).
IL-1β-induced expression of miR-146a-5p is differentiation dependent
Because β-cell sensitivity to cytokines is acquired during β-cell maturation [41], we wished to
examine whether cytokine-mediated induction of miR-146a-5p is also an acquired trait of the
β-cell phenotype. For these studies we used the INSrαβ cells, which in response to Pdx-1
induction progress from an immature to a mature β-cell phenotype [26, 42]. Fig 3D shows the
effect of Pdx-1 induction and/or IL-1β exposure on the expression of miR-146a-5p. The
expression of miR-146a-5p was highly upregulated in response to stimulation with IL-1β both
alone (12 h: 170 fold; 24 h: 440 fold) and together with Pdx1 induction (12 h: 250 fold; 24 h:
660 fold). The expression of miR-146a-5p was not affected by Pdx-1 induction alone, but after
24 h Pdx-1 induction led to an increase in IL-1β-induced miR-146a-5p expression, suggesting
that this regulation is differentiation dependent.
Next, we compared the expression of miR-146a-5p in the mouse β- and α-cell models β-
TC3 and α-TC1 cells to validate the findings in the maturation system. In β-TC3 cells, the
Fig 2. KDACi reduces cytokine-induced expression of miR-146a-5p in human islets. (A) Human islets from three
individual necro-donors were treated with or without 500 nM Givinostat (Giv) 1 h prior to addition of 300 pg/ml IL-
1β, 10 ng/ml IFN-γ, and 10 ng/ml TNF-α (Mix) or no cytokines (Ctrl) for 24 h. miR-146a-5p expression was measured
with qRT-PCR and normalized to the geometric mean of the housekeeping miRs miR-103a and miR-423. Data are
presented as mean ± SEM of 2-ΔCT. p<0.05 (95% confidence interval = -0.04836 to -0.004574), p<0.001 (95%
confidence interval = 0.004108 to 0.005359). (B) Human islets from nine individual necro-donors were left untreated
(control) or treated for 48 h with a mixture of 5000 U/ml TNF-α, 750 U/ml IFN-γ, and 75 U/ml IL-1β (Mix). miR-
146a-5p expression was analyzed by qRT-PCR and presented as ΔCT values after normalizing to let-7c. p<0.05.
https://doi.org/10.1371/journal.pone.0203713.g002
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expression of miR-146a-5p was significantly increased in response to IL-1β alone or in combi-
nation with IFN-γ after 24 h of exposure (Fig 3E). The α-TC1 cells showed no significant
changes in miR-146a-5p expression upon cytokine treatment. Interestingly, the basal expres-
sion of miR-146a-5p was much higher in α-TC1 versus β-TC3 cells. There were no differences
between the two cell lines in the expression of the internal controls Let-7c and Ppia. Taken
together, these results suggest that miR-146a-5p is induced by cytokines preferentially in β-
cells.
miR-146a-5p overexpression inhibits NF-κB signaling, blocks iNOS
expression, and targets TRAF6 and IRAK1
The effects of miR-146a-5p on cytokine-stimulated NF-κB and iNOS promoter activities were
investigated by the use of promoter-luciferase constructs in INS1 cells (Fig 4). Transfection
with miR-146a-5p significantly reduced IL-1β-stimulated NF-κB promoter activity by ~50%,
as compared to transfection with a control miR oligo (Fig 4A), indicating that miR-146a-5p
inhibits this signaling pathway. Furthermore, miR-146a-5p was able to completely block IL-
1β-induced iNOS promoter activity (Fig 4B), and transfection with miR-146a-5p significantly
decreased cytokine-induced NO production as compared to transfection with a control miR
oligo (Fig 4C). Consistent with these observations, miR-146a-5p transfection caused a ~50%
reduction in IL-1β-induced iNOS protein expression (Fig 4D and Fig A in S4 Fig).
Fig 3. miR-146a-5p expression in α- and β-cell lines. (A) INS1 cells were exposed to IL-1β (160 pg/ml) for 6 h, 12 h
and 24 h. The expression of miR-146a-5p normalized to the internal control let-7c was quantified with qRT-PCR.
Mean ± SEM (n = 5). (B) INS1 cells were exposed to IL-1β (160 pg/ml), IFN-γ (5ng/ml) or TNF-α (10 ng/ml) or a
mixture of all three cytokines for 8 h. The expression of miR-146a-5p normalized to the internal control let-7c was
quantified with qRT-PCR. Mean ± SEM (n = 3). (C) The Luciferase promoter assay was conducted in INS1 cells
exposed to IL-1β (160 pg/ml) for 6 h or IL-1β (160 pg/ml) and IFN-γ (5 ng/ml) for 6 h. The cells were pre-treated with
transient transfection mix containing both miR-146a-5p promoter construct and a Renilla construct. Mean ± SEM
(n = 4). (D) miR-146a-5p expression in the INSrαβ cell line with or without induced Pdx-1 by addition of doxycycline
for 24 h prior to cytokine exposure to IL-1β (150 pg/ml) for 2 h, 12 h, or 24 h. The expression of miR-146a-5p and let-
7c was quantified using qRT-PCR. Mean ± SEM (n = 4–5). (E) α-TC1 and β-TC3 cells were exposed for 24 h to IL-1β
(160 pg/ml) or IL-1β (160 pg/ml) and IFN-γ (5 ng/ml). The expressions of both miR-146a-5p and the internal control
let-7c were quantified by qRT-PCR. Mean ± SEM (n = 6–8). p<0.05;  p<0.01;  p<0.001.
https://doi.org/10.1371/journal.pone.0203713.g003
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TRAF6 and IRAK1 are known validated targets of miR-146a-5p [34, 43], and we wished to
confirm this in INS1 cells. Transfection with miR-146a-5p mimics reduced TRAF6 and
IRAK1 protein expression in the presence and absence of IL-1β, and co-transfection with anti-
miR-146a-5p restored their expression (Fig A in S4 Fig). We then investigated whether miR-
146a-5p was able to target a reporter gene construct containing the luciferase gene and the
native 3’UTR of TRAF6 or IRAK1 by co-transfecting each construct with miR-146a-5p mim-
ics. Tranfection with miR-146a-5p caused a ~50% reduction in luciferase activity of both the
TRAF6 and IRAK1 3’UTR reporters, whereas blocking miR-146a-5p with anti-miR-146a-5p
restored and enhanced the luciferase signal (Figs B and D in S4 Fig). Next, the effect of miR-
146a-5p on the mRNA expression of TRAF6 and IRAK1 was examined. Transfection with
miR-146a-5p reduced the mRNA expression levels of TRAF6 and IRAK1 by ~30%, as com-
pared to transfection with a control oligo (Figs C and E in S4 Fig). These results confirm that
TRAF6 and IRAK1 are targets of miR-146a-5p in β-cells, as previously reported [34, 43].
miR-146a-5p inhibits IL-1β-induced MAPK activation
To gain further information about the ability of miR-146a-5p to interfere with IL-1β signaling,
we investigated the effects of transfection with miR-146a-5p on IL-1β-induced phosphoryla-
tions of JNK, p38, and ERK MAPKs which are key signaling components in IL-1β signal trans-
duction. Following transfection of INS1 cells with miR-146a-5p or a negative control miR,
cells were stimulated with IL-1β for 30 min, and cell lysates were analyzed by immunoblotting.
The protein level of the validated miR-146a-5p target TRAF6 was greatly reduced by transfec-
tion with miR-146a-5p, confirming successful delivery of this miR (Fig 5). miR-146a-5p caused
a clear reduction in IL-1β-induced phosphorylations of JNK1/2, p38 and ERK1/2 (Fig 5), sug-
gesting that miR-146a-5p inhibits IL-1β signaling at a level proximal to MAPKs.
miR-146a-5p expression correlates with diabetes onset in the diabetes-
prone BB-DP rat
Lastly, to provide evidence for a potential role of miR-146a-5p during T1D development, its
expression level was examined in the pancreas from BB-DP rats, an animal model of spontane-
ous autoimmune T1D, at different ages. The miR-146a-5p expression level in pancreata from
Fig 4. miR-146a-5p overexpression inhibits NF-κB signaling and blocks iNOS expression. (A) The Luciferase
promoter assay was performed in INS1 cells with a NF-κB promoter construct driving Firefly luciferase. The cells were
pre-treated with transient transfection mix containing both miR-146a-5p promoter construct and a Renilla construct
as internal control. Additionally, the INS1 cells were transiently transfected with a control oligo or a synthetic miR-
146a-5p oligo, and exposed to media with or without IL-1β (160 pg/ml) for 6 h. The relative fold change in ratio
between Firefly/Renilla luciferase is plotted. Mean ± SEM (n = 4). (B) iNOS activity was measured by luciferase assay as
described above. Mean ± SEM (n = 4). (C) NO in medium from INS1 cells transfected with either a control oligo or a
synthetic miR-146a-5p 24 h prior to exposure to IL-1β (160 pg/ml) and IFN-γ (5 ng/ml). Mean ± SEM (n = 4). (D)
iNOS protein expression was analyzed by Western blotting from INS1 cells transfected with either a control oligo or a
synthetic miR-146a-5p 24 h prior to exposure to IL-1β (160 pg/ml) and IFN-γ (5 ng/ml). Mean ± SEM (n = 4).
p<0.05.
https://doi.org/10.1371/journal.pone.0203713.g004
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120 day old and overtly diabetic BB-DP rats showed a significant increase in miR-146a-5p
expression compared with pre-diabetic rats (combined group of 37- or 53-day old rats) (Fig 6).
These data show that the pancreatic expression level of miR-146a-5p gradually increased over
age peaking around the onset of diabetes in BB-DP rats.
Discussion
In this study, we pursued to identify miRs potentially involved in the protective effect of
KDACi against cytokine-induced β-cell apoptosis, with the perspective of identifying miRs as
novel modifiers of diabetes pathogenesis. Our miR microarray identified thirteen miRs (miR-
7a-2-3p, miR-29c-3p, miR-96-5p, miR-101a-3p, miR-140-5p, miR-146a-5p, miR-146b-5p,
miR-340-5p, miR-384-5p, miR-455-5p, miR-466b-2-3p, miR-652-5p, and miR-3584-5p) that
were regulated by both pro-inflammatory cytokines and by the pan-KDACi Givinostat, and
nine of these were examined by qRT-PCR. Being the most markedly regulated miR in the miR
array and qRT-PCR analyses, we chose to focus our functional studies on miR-146a-5p.
The expression of miR-146a-5p has previously been shown to be induced by pro-inflamma-
tory cytokines in human islets and in the mouse β-cell line MIN6 [43, 44]. Here, we have con-
firmed that miR-146a-5p was highly upregulated by cytokines in rat and human islets as well
Fig 5. miR-146a-5p inhibits IL-1β-induced phosphorylation of JNK, p38 and ERK MAPK. Representative Western
blot of TRAF6, p-JNK1/2, p-p38, p-ERK1/2, and β-actin (n = 4). INS1 cells were transiently transfected with a negative
control oligo or a synthetic miR-146a-5p oligo for 48 h, and exposed to media with or without IL-1β (160 pg/ml) for 30
min.
https://doi.org/10.1371/journal.pone.0203713.g005
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as in the rat β-cell line INS1, likely as an adaptive response ensuing IL-1β-induced NF-κB acti-
vation, since the miR-146a promoter contains NF-κB binding elements [34, 43, 45]. Of note, a
study in human alveolar epithelial cells showed that IL-1β-induced miR-146a-5p expression is
dependent on both NF-κB and JNK1/2 [46], which could also be a possible regulatory mecha-
nism in β-cells, since IL-1β induces JNK1/2 activity in islet cells [47].
KDACi reduced the cytokine-induced expression of miR-146a-5p in INS1 cells after 6 h
and in human islets after 24 h, reflecting the known action of KDACi to block inflammatory
Fig 6. miR-146a-5p expression in the BB-DP rat T1D animal model. The expressions of miR-146a-5p and the
internal control let-7c were analyzed by qRT-PCR on whole pancreas RNA from rats sacrificed at day 37, 53, 80, 120 or
at diabetes onset (n = 3–6 in each group). Mean ± SD of data plotted as fold change compared to day 37. p<0.05.
https://doi.org/10.1371/journal.pone.0203713.g006
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cytokine signaling by reducing NF-κB transcriptional activity [14]. In contrast, KDACi
enhanced the cytokine-induced miR-146a-5p expression in INS1 cells after 18 h and 24 h of
exposure. In INS1 cells cytokine signaling inducing inflammatory gene expression is rapid
(<6 h) [14], and gene expression patterns determined after 24 h of cytokine exposure in INS1
cells are therefore a combination of alterations secondary to changes in the transcription of
early immediate response genes and compensatory/restorative responses. In human islets,
such responses would be expected to be delayed relative to those observed in INS1 cells due to
the known lower sensitivity of human islets to cytokines [3] and would only be apparent in
prolonged time-response experiments. The early transient reduction in miR-146a-5p expres-
sion may therefore be collateral effect of KDACi on the transcriptional activity of NF-κB,
whereas a later more persistent augmentation of cytokine-induced miR-146a-5p expression is
likely to be a protective response caused by histone hyperacetylation of the chromatin region
harboring the miR-146a-5p gene, and directed at counteracting the adverse impact of inflam-
mation. In support of this, previous studies have shown that KDACi increased IL-1β-induced
miR-146a-5p expression in osteoarthritis fibroblast-like synoviocytes [48] and upregulated
basal as well as lipopolysaccharide (LPS)-stimulated miR-146a-5p expression in macrophages
isolated from mice [49].
miR-146a-5p is a known inhibitor of IL-1 signaling in many cell types at least in part by
directly targeting TRAF6 and IRAK1 [34, 43, 50]. Roggli et al. showed that transfection with
miR-146a-5p mimics reduced basal and cytokine-induced TRAF6 and IRAK1 reporter activity
in MIN6 cells [43]. Here, we confirmed a reduction in the reporter activity as well as mRNA
and protein levels of TRAF6 and IRAK1 in INS1 cells after transfection with miR-146a-5p
mimics, supporting the evidence that TRAF6 and IRAK1 are direct targets of miR-146a-5p in
β-cells. Transfection of INS1 cells with miR-146a-5p also reduced the activity of the NF-κB
and iNOS promotors resulting in decreased cytokine-induced iNOS protein expression and
NO synthesis. Cytokine-induced MAPK signaling was also decreased after transfection with
miR-146a-5p. Our results indicate that miR-146a-5p downregulates islet inflammation and β-
cell death in part by impaired NF-κB and MAPK signaling, which is in line with studies in
other cell types such as lymphocytes, adipocytes, and a renal cell line [51–53].
To our knowledge, this is the first report to show islet cell selectivity in inflammatory miR-
146a-5p induction. We found that cytokines only increased miR-146a-5p expression in a β-cell
(β-TC3) but not in an α-cell (α-TC1) line. Furthermore, a surprisingly high basal expression
level of miR-146a-5p was observed in α-TC1 cells compared to β-TC3 cells, indicating that
cytokine-independent factors expressed in α-cells induce a higher basal level of miR-146a-5p.
Interestingly, the miR-146a-5p promoter also contains binding sites for OCT-1, which in
Mutu cells have been shown to play a substantial role in facilitating constitutive miR-146a-5p
expression [45], and the expression level of OCT-1 is higher in α-cells compared to β-cells
based on publicly available array data (www.t1dbase.org). We found cytokine-induced miR-
146a-5p expression to be more prominent in Pdx-1 overexpression-driven β-cell maturation.
Since miR-146a-5p targets proximal IL-1 signaling components, a high basal expression level
could contribute to the α-cell resistance to cytokines. Moreover, blunted IL-1β signaling in α-
cells [54] may explain the impaired cytokine-induced miR-146a-5p expression in α- compared
to β-cells.
miR-146a-5p is regulated by other mediators of β-cell dysfunction than cytokines, such as
high glucose [43, 44] and palmitate [55]. miR-146a-5p was increased by 2.8-fold in islets of lep-
tin-deficient ob/ob obese diabetes-resistant mice compared with lean mice, but only induced
by 1.2-fold in diabetes-prone non-diabetic mice [56]. Islets from the non-obese diabetes
(NOD) mouse model also expressed increased miR-146a-5p levels at disease-onset [43, 57],
and miR-146a-5p was increased in the islets of adult diabetic mice [58]. Our observation that
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miR-146a-5p was elevated in diabetes-prone BB-DP rat pancreas at diabetes onset strengthens
the body of evidence for the potential role of miR-146a-5p in β-cell death and T1D.
Cytokines induce miR-146a-5p expression in human monocytes [34], and the expression of
miR-146a-5p is dysregulated in peripheral blood mononuclear cells from T1D patients [59].
Moreover, miR-146a-5p-deficient mice develop a severe myeloproliferative syndrome, leading
to autoimmune or inflammatory diseases before 24 weeks of age [60]. Taken together with evi-
dence discussed in the preceding paragraphs, these observations support a protective role for
miR-146a-5p against inflammatory and autoimmune mechanisms leading to diabetes. It is
gratifying that our unbiased array approach in INS1 cells identified the importance of this
miR, underpinning the strength of an approach using interventions, i.e. KDACi, to reveal
novel candidate miRs of therapeutic potential. Future studies should pay attention also to
other miRs modulated by KDACi in INS1 cells and confirm their expression in human islets
as well, and such work is in progress.
In conclusion, our data together with the majority of the literature point towards a protec-
tive role of miR-146a-5p against cytokine-induced β-cell apoptosis and suggest that long-term
expression of miR-146a-5p can be enhanced by KDACi via epigenetic modification. The study
by Roggli et al. suggested a pro-apoptotic effect of miR-146a-5p in β-cells [43]. This apparent
controversy illustrates the complexity of miR biology, where the duration and the intensity of
miR-146a-5p overexpression may differently impact β-cell function and survival, and where
the kinetics and inflammatory context of changes in miR-146a-5p levels may determine if
miR-146a-5p attenuates inflammation or favors apoptosis. Thus, the role of miR-146a-5p as a
pathogenetic or a protective factor in diabetes is yet not finally settled. It remains to be investi-
gated whether the miR-146a-5p expression level in β-cells is adequate to constitute an efficient
apoptosis brake in vivo. Antagomirs, either in the form of locked nucleic acids (LNAs) or short
oligonucleotides, have shown activity in vivo in disease models e.g. of genetic hypercholesterol-
emia [61, 62]; anti-miR-146a-5p antagomirs should be tested in diabetic animal models to
evaluate the translational potential of our findings.
Supporting information
S1 Fig. KDACi reduced cytokine-induced apoptosis and NO accumulation in INS1 cells.
INS1 cells were left untreated (-), treated with 1 μM CI994 or 125 nM Givinostat (Giv.) 1 h
prior to addition of 0.1 ng/mL IFN-γ plus 37–150 pg/mL IL-1β (as indicated) or no cytokines
(Ctrl) for 24 h. (A) Apoptosis as % of control measured with the Cell Death Detection ELISA
from Roche. Data are presented as mean ± SEM (n = 4–10). (B) The media were analyzed
for nitrite using the NO assay. Data are presented as mean ± SEM (n = 3–11). Statistical
significance of paired t-test is shown in the graphs (p<0.05, p<0.01, p<0.001 and
p<0.0001).
(TIF)
S2 Fig. Target prediction and regulatory interaction networks of identified miR groups.
The figure depicts regulatory interaction networks (RINs) of miR-targets for group A (S2A),
group B (S2B) and group’s c and d (S2C). Each RIN includes two types of nodes: the miRs
(cyan) and their predicted targets (pink) as identified from miRTarBase and TargetScan data-
bases. The color of the connecting arrows for each RIN represents the two databases: miRTar-
Base (blue) and TargetScan (red).
(TIF)
S3 Fig. Cytokine-induced miR-146a-5p expression in rat islets. (A) The miR-146a-5p
expression was analyzed by qRT-PCR analysis in isolated rat islets exposed to IL-1β (160 pg/
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ml) or a combination of IL-1β (160 pg/ml) and IFN-γ (5 ng/ml). The data is presented as the
mean of two experiments. The miR-146a-5p data was normalized to the internal control, let-
7c. (B) Expression of let-7c treated with IL-1β (160 pg/ml) and a mix of IL-1β (160 pg/ml) and
IFN-γ (5 ng/ml) for 24 h is stable.
(TIF)
S4 Fig. miR-146a-5p targets TRAF6 and IRAK1 in INS1 cells. (A) Representative Western
blot of iNOS, TRAF6, IRAK1 and β-actin (n = 4). INS1 cells were transiently transfected with a
control oligo, miR-146a-5p, or anti-anti-miR-146a-5p oligo for 48 h, and exposed to media
with or without IL-1β (160 pg/ml) for 6 h. (B) The luciferase assay was performed in INS1 cells
transfected with luciferase gene and native 3’UTR constructs of TRAF6 together with control
oligo, miR-146a-5p, or anti-miR-146a-5p oligo 24 h prior to harvest. Means ± SEM (n = 4).
(C) INS1 cells were transfected with control oligo or miR-146a-5p for 48 h hours prior to
RNA extraction, and mRNA levels of TRAF6 normalized to PPIA levels were determined by
qRT-PCR. Means ± SEM (n = 3). (D) INS1 cells were transfected with luciferase gene and
native 3’UTR constructs of IRAK1 together with control oligo, miR-146a-5p, or anti-miR-
146a-5p oligo 24 h prior to harvest. Means ± SEM (n = 4). (E) INS1 cells were transfected with
control oligo or miR-146a-5p for 48 h prior to RNA extraction, and mRNA levels of IRAK1
normalized to PPIA levels were determined by qRT-PCR. Means ± SEM (n = 3). p<0.05.
(TIF)
S1 Table. Functional annotation clustering of miR-targets from the selected four groups.
The clustering of gene ontology (GO) biological process (BP) terms was performed in DAVID.
Representative biological terms associated for each enriched cluster (group enrichment
score > 1.3) are shown along with total number of genes in each cluster (Count) and gene
names (Genes).
(DOCX)
S2 Table. Two-way ANOVA test statistics of qRT-PCR, apoptosis and NO results.
(DOCX)
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